Drug intelligence / Profile preview

amitriptyline + fluoxetine

Development stage
Preclinical
Lead developer
Eli Lilly
Modality
Small Molecules
Administration
Oral
01

Overview

Amitriptyline + fluoxetine is a combination of two antidepressant medications, each with distinct mechanisms of action. Amitriptyline is a tricyclic antidepressant (TCA) that primarily inhibits the reuptake of norepinephrine and serotonin, increasing their levels in the central nervous system. Fluoxetine is a selective serotonin reuptake inhibitor (SSRI) that selectively blocks the reuptake of serotonin, enhancing serotonergic neurotransmission. This combination has been used off-label for treatment-resistant depression but carries significant risk due to pharmacokinetic interactions—fluoxetine inhibits CYP2D6, which metabolizes amitriptyline, leading to increased plasma concentrations and potential toxicity. The use of this combination requires careful monitoring due to risks such as serotonin syndrome and cardiac toxicity[3][4][7][9].

02

Targets

NET (Norepinephrine Transporter)ADRA1A (α1A)M1 (Muscarinic acetylcholine receptor M1)HRH1 (Histamine H1 Receptor)

Beyond the preview

Go deeper on amitriptyline + fluoxetine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on amitriptyline + fluoxetine.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call